|
Characteristic
|
Total [cases (%)]
|
ATG5 rs473543 genotype [cases (%)]
|
P
|
|---|
|
AA
|
GG
|
GA
|
|---|
|
Total
|
316
|
60
|
112
|
144
| |
|
Age (years)
|
0.233
|
|
≤ 40
|
74 (23.4)
|
11 (18.3)
|
23 (20.5)
|
40 (27.8)
| |
|
> 40
|
242 (76.6)
|
49 (81.7)
|
89 (79.5)
|
104 (72.2)
| |
|
T stage
|
0.231
|
|
pT0–T1
|
156 (49.4)
|
35 (58.3)
|
50 (44.6)
|
71 (49.3)
| |
|
pT2–T4
|
160 (50.6)
|
25 (41.7)
|
62 (55.4)
|
73 (50.7)
| |
|
Axillary lymph node status
|
0.543
|
|
Negative
|
199 (63.0)
|
41 (68.3)
|
67 (59.8)
|
91 (63.2)
| |
|
Positive
|
117 (37.0)
|
19 (31.7)
|
45 (40.2)
|
53 (36.8)
| |
|
TNM stage
|
0.948
|
|
0–I
|
109 (34.5)
|
20 (33.3)
|
38 (33.9)
|
51 (35.4)
| |
|
II–III
|
207 (65.5)
|
40 (66.7)
|
74 (66.1)
|
93 (64.6)
| |
|
Pathological type
|
0.855
|
|
Invasive ductal carcinoma
|
294 (93.0)
|
58 (96.7)
|
102 (91.1)
|
134 (93.1)
| |
|
Grade 1/2
|
109 (34.5)
|
24 (40.0)
|
37 (33.0)
|
48 (33.3)
| |
|
Grade 3
|
164 (51.9)
|
30 (50.0)
|
57 (50.9)
|
77 (53.5)
| |
|
Unknown
|
21 (6.6)
|
4 (6.7)
|
8 (7.1)
|
9 (6.3)
| |
|
Others
|
22 (7.0)
|
2 (3.3)
|
10 (8.9)
|
10 (6.9)
| |
|
Vascular invasion
|
0.594
|
|
Yes
|
46 (14.6)
|
7 (11.7)
|
15 (13.4)
|
24 (16.7)
| |
|
No
|
270 (85.4)
|
53 (88.3)
|
97 (86.6)
|
120 (83.3)
| |
|
Adjuvant radiotherapy
|
0.396
|
|
Yes
|
121 (38.3)
|
21 (35.0)
|
39 (34.8)
|
61 (42.4)
| |
|
No
|
195 (61.7)
|
39 (65.0)
|
73 (65.2)
|
83 (57.6)
| |
|
Chemotherapeutic regimensa
|
0.455
|
|
Anthracycline-based
|
222 (70.3)
|
43 (71.7)
|
67 (59.8)
|
112 (77.8)
| |
|
Taxane-based
|
251 (79.4)
|
47 (78.3)
|
95 (84.8)
|
109 (75.7)
| |
|
Anthracycline-taxane combination
|
157 (70.7)
|
30 (50.0)
|
50 (44.6)
|
77 (53.5)
| |
- aPatients who received anthracyclines as chemotherapeutic treatment may also receive taxanes as chemotherapy at the same time. Double counting resulted in the sum higher than the number of subjects investigated in this study
